Company to host Key Opinion Leader webinar on September 12 at 2:00 pm CT/3:00 pm ET

LYON, France and CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced the acceptance of a late-breaking oral presentation and an additional poster presentation, including Phase 2a data for AZP-3601, its lead therapeutic peptide for hypoparathyroidism, at the American Society for Bone and Mineral Research 2022 Annual Meeting (ASBMR), which is being held September 9-12 in Austin, TX. The company will also be hosting a Key Opinion Leader (KOL) webinar on Monday, September 12, 2022 at 2:00 pm CT/3:00 pm ET to review the data in more detail.

Presentation details: Title: Efficacy and Safety of AZP-3601, a Novel Investigational Long-Acting PTH Analog for Treatment of Hypoparathyroidism. Results From the First Cohort of a 3-Month Multi-Center Open Label Phase 2a Study Format: Late-breaking oral presentation Date: Monday, September 12, 2022 Session time: 11:30 am-12:45 pm CT (12:30 pm-1:45 pm ET) Presentation time: 11:30 am-11:45 am CT (12:30 pm-12:45 pm ET) Author/Presenter: István Takács, M.D. (Semmelweis University, Budapest, Hungary), author and lead investigator of the study

Title: Development of the Hypoparathyroidism Daily Diary of Symptom Experience (HPT-DD-SE) and the Hypoparathyroidism Life Impact Questionnaire (HPT-LIQ) Format: Poster presentation (Poster Session II & Poster Tours) Date: Sunday, September 11, 2022 Session time: 1:00 pm – 3:00 pm CT (2:00 pm-4:00 pm ET) Author/Presenter: Rebecca Crawford (RTI Health Solutions)

Key Opinion Leader Webinar: Amolyt will host a KOL webinar to discuss these Phase 2a results in more detail on Monday, September 12, 2022 at 2:00 pm CT (3:00 pm ET). Interested parties can register for the webinar here.

About Hypoparathyroidism Hypoparathyroidism is defined by a deficiency of parathyroid hormone (PTH) that results in decreased calcium and elevated phosphorus levels in the blood. About 80% of the approximately 80,000 people in the U.S. and 110,000 in the European Union with hypoparathyroidism are women. Despite available treatments, patients experience persistent, life-altering symptoms and often develop complications and comorbidities that diminish quality of life and create segments of the patient population with specific clinical needs. Clinical manifestations of hypoparathyroidism impact a large number of tissues and organ systems, and in particular, the kidneys and bone. 17% of patients with hypoparathyroidism have osteopenia or osteoporosis and 53% are peri- or postmenopausal women with an increased risk of developing osteoporosis. Approximately 26% of patients with hypoparathyroidism have chronic kidney disease or failure, highlighting the importance of reducing urinary calcium excretion as a key treatment goal.

About AZP-3601 AZP-3601 is an investigational therapeutic peptide designed to target a specific conformation of the parathyroid hormone (PTH) receptor to safely produce sustained and stable levels of calcium in the blood and thereby manage the symptoms of hypoparathyroidism, and to limit urine calcium excretion by restoring calcium reabsorption by the kidney, with the goal of consequently preventing chronic kidney disease. In addition to its unique receptor profile, AZP-3601 is also designed to have a short half-life to potentially preserve bone integrity, an important benefit, since the majority of patients are peri- and postmenopausal women with an increased risk of developing osteoporosis.

About Amolyt Pharma  Amolyt Pharma, a clinical stage biotechnology company, is building on its team’s established expertise in therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Its development portfolio includes AZP-3601, a long-acting PTH analog as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors. To learn more, visit https://amolytpharma.com/ or follow us on Twitter and LinkedIn.

Media: Cherilyn Cecchini, M.D. LifeSci Communications ccecchini@lifescicomms.com +1.646.876.5196

Investors: Ashley Robinson LifeSci Advisors, LLC arr@lifesciadvisors.com +1.617.430.7577

The FDA offered mixed messages Friday for Amylyx Pharmaceuticals' experimental neurological disease treatment, and AMLX stock crashed.

The patent is expected to provide the company with exclusivity for its experimental RNAi therapeutic until at least April 2038.

By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Exebacase Active in Rabbit Model of MRSA Implant-Associated Osteomyelitis On July 15, 2022, ContraFect Corp. (NASDAQ:CFRX) announced the publication of results in the Journal of Bone and Joint Infection from a preclinical rabbit model of implant-associated methicillin-resistant Staphylococcus aureus (MRSA)

Life expectancy at birth in the U.S. has fallen by nearly three years since the beginning of the Covid-19 pandemic, according to new provisional data from the Centers for Disease Control. In 2019, before the pandemic began, life expectancy in the U.S. was 78 years and 10 months. In 2020, it fell to 77 years, due largely to deaths from Covid-19. In 2021, life expectancy fell for a second consecutive year, to 76 years and 1 month – about the same level it was a quarter century earlier. Interesting

The life expectancy for Americans dropped for the second year in a row, according to new data released by the National Center for Health Statistics Wednesday.

Shares of Dollar Tree Inc. fell 1.0% in afternoon trading Friday, and the Canada-listed shares of Dollarama Inc. slipped 0.4%, after Canada's Environment Defence announced this week

Two years after raising $277 million in its IPO, a Watertown biotech developing drugs for blood diseases is being acquired by Novo Nordisk.

Novo Nordisk (NVO) inks agreement to acquire Forma Therapeutics for $1.1 billion. The company is looking to venture into the sickle cell disease and rare blood disorders space.

There are no approved therapies for people with Huntington's disease, an inherited neurodegenerative disease that can unset in the 30s and 40s with jerky muscle movements and drastic changes in behavior.

Amgen stock jumped Wednesday after outperforming expectations in a lung-cancer study. It brought rival Mirati along for the ride.

All the reasons why you need more of this sunshine vitamin in your life, plus the best vitamin D food sources and how much you should be getting in your diet.

Trying to lose weight in a healthy, long-term, sustainable way can be a frustrating process sometimes because every individual has their own unique needs. Meaning, that despite our wishes, there is no single "miracle" solution for reaching our goals. Instead, it often requires us to get to know ourselves and what our bodies need, while making small but impactful changes to our daily routine, to successfully lose weight.And sometimes, even when we've made these changes, we can still hit some road

The updated shots, designed to work against the current variations of Covid-19, come as people return to schools and offices and holidays approach.

One of Atlanta's largest hospitals said it plans to shut down in two months after experiencing more than $100 million in losses over the past year. Wellstar Health System announced late Wednesday that the Atlanta Medical Center will close Nov. 1. The hospital operates a busy emergency room and is a vital health care provider for many low-income residents.

A former ShorePoint Health Venice employee filed the lawsuit Aug. 29 — on behalf of herself and approximately 600 other employees — alleging CHS and the hospital violated the Worker Adjustment and Retraining Notification Act.

Parade.com has an extensive editorial partnership with Cleveland Clinic, consistently named as one of the nation's best hospitals in U.S. News & World Report's annual "America's Best Hospitals" survey. Click here to learn more about our health reporting policies. Taking diet pills, exercising ...

Catalyst Pharmaceuticals is now looking for its second act after launching a LEMS treatment. Could CPRX stock investors see a buyout?

The FDA approves Sanofi's (SNY) Xenpozyme for treating non-central nervous system (non-CNS) manifestations of acid sphingomyelinase deficiency (ASMD) disease.

Bayer AG agreed to pay $40 million to settle claims over its alleged use of kickbacks and false statements related to three prescription drugs, the U.S. Department of Justice said on Friday. The settlement arose from whistleblower lawsuits filed in 2005 and 2006 in New Jersey by Laurie Simpson, a former Bayer employee who worked in its marketing department and accused the German company of violating the federal False Claims Act. Bayer did not admit wrongdoing in agreeing to settle.

Government data show the U.S. had a major drop in life expectancy in 2021. Here’s why this happened, and what caused it.